Dyne Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary
Dyne Therapeutics, Inc. reported a quarterly adjusted loss of $1.06 per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -76 cents. The mean expectation of sixteen analysts for the quarter was for a loss of 91 cents per share. Wall Street expected results to range from $-1.09 to -73 cents per share.
Reported revenue was zero; analysts expected zero.
Dyne Therapeutics, Inc.'s reported EPS for the quarter was a loss of $1.06.
The company reported a quarterly loss of $193.55 million.
Dyne Therapeutics, Inc. shares had risen by 15.1% this quarter and lost 5.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 1.7% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Dyne Therapeutics, Inc. is $36.50, about 49.2% above its last closing price of $18.54
This summary was machine generated from LSEG data November 5 at 03:16 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2026 | -0.91 | -1.06 | Missed |
Jun. 30 2026 | -0.75 | -1.08 | Missed |
Mar. 31 2026 | -0.77 | -0.73 | Beat |
Dec. 31 2025 | -0.77 | -0.76 | Beat |